Evidence map›Paper›PMID 40080018›Full record

ArticleJAMA network open2025

Area Socioeconomic Status, Vaccination Access, and Female Human Papillomavirus Vaccination.

Emiko Oka, Megumi Okada, Yoshiko Ikuno, Kokoro Amano, Sakiko Shioya, Migiri Kawabata, Rie Sakurai, Miki Konishi, Tomoki Nakaya, Kota Katanoda and 2 more

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emiko OkaDepartment of Medical Statistics, Research and Development Center, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Megumi OkadaOsaka City Public Health Office, Osaka, Japan.
Yoshiko IkunoDepartment of Health Promotion, Public Health Bureau, Osaka City, Osaka, Japan.
Kokoro AmanoDepartment of Health Promotion, Public Health Bureau, Osaka City, Osaka, Japan.
Sakiko ShioyaDepartment of Health Promotion, Public Health Bureau, Osaka City, Osaka, Japan.
Migiri KawabataOsaka City Hirano Ward Health and Welfare Center, Osaka, Japan.
Rie SakuraiOsaka City Public Health Office, Osaka, Japan.
Miki KonishiOsaka City Abeno Ward Health and Welfare Center, Osaka, Japan.
Tomoki NakayaGraduate School of Environmental Studies, Tohoku University, Miyagi, Japan.
Kota KatanodaDivision of Population Data Science, National Cancer Center Institute for Cancer Control, Tokyo, Japan.
Yutaka UedaDepartment of Obstetrics and Gynecology, Osaka University, Osaka, Japan.
Yuri ItoDepartment of Medical Statistics, Research and Development Center, Osaka Medical and Pharmaceutical University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Although evaluation of geographic area inequities in vaccination is crucial to identify areas that need community-based interventions, knowledge of disparities in human papillomavirus (HPV) vaccination uptake remains limited in Japan. Objective: To investigate the association of female cumulative HPV vaccination uptake with neighborhood-based socioeconomic status and access indicators in Osaka City, Japan. Design, Setting, and Participants: This population-based, cross-sectional study included HPV vaccination data for fiscal year (April 1 to March 31) 2013 to fiscal year 2022 provided by Osaka City. The study population comprised the total number of girls eligible for HPV vaccination born between fiscal years 1997 and 2010. Exposure: The area deprivation index (ADI) was used as a neighborhood-based socioeconomic status indicator, and the number of medical facilities providing HPV vaccination within a 500-m range of a representative point in each geographic area was used as an access indicator. Main Outcomes and Measures: The primary outcome was cumulative uptake, defined as the cumulative number of girls receiving at least 1 dose and those completing all doses (3 doses until March 2023), by neighborhood ADI and access indicators. A Poisson regression model with robust variance was applied to assess the association of neighborhood-level indicators with cumulative HPV vaccination uptake. Results: In Osaka City, 185 373 girls (median [IQR] age at vaccination, 16 [14-19] years) were eligible for HPV vaccination, of whom 18 688 (10.1%) received at least 1 dose of HPV vaccine. Compared with girls living in areas with the most deprivation (2539 of 28 078 [9.0%]), those living in areas with the least deprivation (4889 of 42 170 girls [11.6%]) had a greater cumulative HPV vaccination uptake (prevalence ratio [PR], 1.25; 95% CI, 1.16-1.34). In addition, compared with girls living in areas with low medical facility access (5128 of 55 055 [9.3%]), those residing in high-access areas (5862 of 54 740 [10.7%]) had a greater cumulative vaccination uptake (PR, 1.09; 95% CI, 1.03-1.16). Cumulative HPV vaccination was significantly associated with ADI in routine vaccination (least vs most deprivation: PR, 1.46; 95% CI, 1.33-1.61) but not in catch-up vaccination (least vs most deprivation: PR, 1.01; 95% CI, 0.92-1.11). Conclusions and Relevance: In this cross-sectional study of area deprivation, vaccination access, and HPV vaccination status, higher socioeconomic status and higher medical facility access were associated with higher cumulative HPV vaccination uptake. These findings suggest that further strategies, including a socioecologic approach, are needed to increase HPV vaccination and reduce disparities in uptake.

Indexed as

Health Services AccessibilityPapillomavirus InfectionsPapillomavirus VaccinesSocial ClassVaccinationAdolescentCross-Sectional StudiesFemaleHealthcare DisparitiesHuman Papillomavirus VirusesHumansJapanPapillomavirus Vaccines

Identifiers

PMID40080018
PMCPMC11907311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.